Arcticzymes Technologies ASA
The answer first
Does Arcticzymes Technologies beat the market?
No, Arcticzymes Technologies has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 44% of Nordic stocks
- Quality79
- Value14
- Trend55
No. 72 of 195 in healthcare
Expectations in the price
High expectations
For the share to return about 9% a year from today's price, the cash Arcticzymes Technologies keeps must grow about 24% a year for 10 years.
Max for seven days
Follow Arcticzymes Technologies with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Arcticzymes Technologies
Your first answer is free, no account needed.
Do you own Arcticzymes Technologies, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Arcticzymes Technologies and a few more. Free, no card.
Super Stock+44.6%In short
- Arcticzymes Technologies has fallen 5.4% over the past year, including dividends.
- Overall, Arcticzymes Technologies ranks better than 44% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 86.4%. The price is 81.1% below its peak now.
What do analysts think of Arcticzymes Technologies?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 44% of Nordic stocks.
No. 72 of 195 in healthcare
High A solid company: it earns well on its money and has healthy finances.
No. 56 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.06
- Asset turnoverSales divided by everything the company owns0.34
- Return on equityProfit divided by equity+4.0%
- Cash conversionOperating cash flow divided by profit1.54
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 121 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity3.0
- P/SPrice divided by sales8.1
- P/EPrice divided by earnings75.5
- P/CFPrice divided by operating cash flow49.1
The ranking is built on P/E, P/B and P/S.
Medium The share price has moved about like most stocks over the last year.
No. 69 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months+1.0%
- 6 months+5.5%
- 9 months−8.7%
- 12 months−5.4%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own Arcticzymes Technologies
7 funds we follow own Arcticzymes Technologies. The share is how much of the fund the stock makes up.
- Norway5
- Sweden2
- Lannebo Hälsa och Ny Teknik ASweden · Lannebo0.9%
- Didner & Gerge Small & MicrocapSweden · Didner0.5%
- Alfred Berg Indeks CNorway · Alfred Berg0.0%
- DNB Norge Indeks ANorway · DNB0.0%
- KLP AksjeNorge Indeks IINorway · KLP0.0%
- KLP AksjeNorge Indeks NNorway · KLP0.0%
- Storebrand Indeks Norge ANorway · Storebrand0.0%
From the funds' latest known holdings.
About Arcticzymes Technologies
Arcticzymes Technologies ASA is a company in healthcare, listed on Oslo Børs. The share trades in NOK. It has around 50 employees.
ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, in vitro diagnostics, and biomanufacturing. The company offers shrimp alkaline phosphatase; cod UNG for use in viral and other molecular diagnostic assays for the removal of contaminating dU-DNA; salt active nucleases for the removal of nucleic acids during manufacturing of viral vectors, recombinant proteins, and other reagents; and double-strand specific DNases and derived kits for the removal of double stranded DNA.


See the full analysis of Arcticzymes Technologies.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card